Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amoxicillin trihydrate,potassium clavulanate -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - amoxicillin trihydrate,potassium clavulanate -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose; sodium lauryl sulfate; cetyl alcohol - short-term treatment of bacterial infections at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms: skin and skin structure infections. urinary tract infections (complicated and uncomplicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxycillin/clavulanic acid tablet preparations. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptible studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections cause by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxycillin/clavulanic acid tablet preparations should not require the addition of another antibiotic due to the amoxycillin content of these products.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

devatis pty ltd - amoxicillin trihydrate, quantity: 91.823 mg/ml; potassium clavulanate, quantity: 13.58 mg/ml - suspension, powder for - excipient ingredients: xanthan gum; hypromellose; silicon dioxide; saccharin sodium; methyl hydroxybenzoate; succinic acid; colloidal anhydrous silica; flavour - amoklavin duo 400/57 (amoxicillin and clavulanic acid) oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology):,skin and skin structure infections,urinary tract infections (complicated and uncomplicated),upper respiratory tract infections including sinusitis and otitis media,lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoklavin duo 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoklavin duo 400/57, should not require the addition of another antibiotic due to the amoxicillin content of amoklavin duo 400/57.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

devatis pty ltd - amoxicillin trihydrate, quantity: 91.823 mg/ml; potassium clavulanate, quantity: 13.58 mg/ml - suspension, powder for - excipient ingredients: saccharin sodium; xanthan gum; methyl hydroxybenzoate; succinic acid; colloidal anhydrous silica; silicon dioxide; hypromellose; flavour - deva-amoxyclav 400/57 (amoxicillin and clavulanic acid) oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology):,skin and skin structure infections,urinary tract infections (complicated and uncomplicated),upper respiratory tract infections including sinusitis and otitis media,lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to deva-amoxyclav 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to deva-amoxyclav 400/57, should not require the addition of another antibiotic due to the amoxicillin content of deva-amoxyclav 400/57.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate,potassium clavulanate -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - potassium clavulanate, quantity: 7.45 mg/ml (equivalent: clavulanic acid, qty 6.25 mg/ml); amoxicillin trihydrate, quantity: 28.7 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - suspension, powder for - excipient ingredients: sodium citrate; purified talc; guar gum; silicon dioxide; aspartame; citric acid; flavour - treatment of the following infections when caused by curam 125/31.25 sensitive, beta-lactamase producing organisms: skin and skin structure infections, including cases caused by beta-lactamase producing staph. aureus, e. coli and klebsiella sp. (only some strains may be sensitive). urinary tract infections, including cases caused by beta-lactamase producing e. coli, p. mirabilis and klebsiella sp. upper respiratory tract infections, such as sinusitis, including cases caused by beta-lactamase producing h. influenzae and m. catarrhalis, and otitis media, especially cases caused by beta-lactamase producing h. influenzae, m. catarrhalis and staph. aureus. lower respiratory tract infections, especially cases caused by beta-lactamase producing h. influenzae and m. catarrhalis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam 125/31.25. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in microbiology, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam 125/31.25 should not require the addition of another antibiotic due to the amoxycillin content of curam 125/31.25.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam tablets should not require the addition of another antibiotic due to the amoxycillin content of curam tablets.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - amoxicillin trihydrate, quantity: 1004.31 mg; potassium clavulanate, quantity: 151.917 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; dichloromethane; microcrystalline cellulose; sodium starch glycollate; isopropyl alcohol; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amclavox duo forte 875/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 573.892 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; dichloromethane; isopropyl alcohol; sodium starch glycollate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amclavox duo 500/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.